CN116889281A - 一种用于提高骨密度的和金钙配方 - Google Patents
一种用于提高骨密度的和金钙配方 Download PDFInfo
- Publication number
- CN116889281A CN116889281A CN202210336806.2A CN202210336806A CN116889281A CN 116889281 A CN116889281 A CN 116889281A CN 202210336806 A CN202210336806 A CN 202210336806A CN 116889281 A CN116889281 A CN 116889281A
- Authority
- CN
- China
- Prior art keywords
- calcium
- formula
- improving bone
- bone mineral
- mineral density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims description 8
- 239000011707 mineral Substances 0.000 title claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000011575 calcium Substances 0.000 claims abstract description 35
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 35
- 102000008186 Collagen Human genes 0.000 claims abstract description 11
- 108010035532 Collagen Proteins 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 11
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 229940013618 stevioside Drugs 0.000 claims abstract description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 9
- 241000208688 Eucommia Species 0.000 claims abstract description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 3
- 244000046146 Pueraria lobata Species 0.000 claims abstract 2
- 239000010931 gold Substances 0.000 claims description 8
- 229910052737 gold Inorganic materials 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 230000037182 bone density Effects 0.000 abstract description 8
- 229940069978 calcium supplement Drugs 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 206010006956 Calcium deficiency Diseases 0.000 abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- ZAZYUFWBENXXPV-UHFFFAOYSA-N calcium gold Chemical compound [Ca].[Au] ZAZYUFWBENXXPV-UHFFFAOYSA-N 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000208689 Eucommia ulmoides Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于提高骨密度的和金钙配方，各成分按重量比为：氨基酸螯合钙0.5～1g、胶原蛋白肽1～5g、杜仲雄花提取物0.1～1g、葛根提取物0.1～1g、低聚果糖1～3g、甜菊苷0.5～1g；本发明根据男女性别不同、年龄不同，发生钙缺乏、钙流失、骨质疏松的机理不同，区分男用型和女用型配方，完美演绎高含量、快吸收、安全转运和长期储存的补钙原则，比传统补钙剂具有更好地补钙、固钙，提高骨密度的作用。
Description
技术领域
本发明属于补钙配方技术领域，尤其涉及一种用于提高骨密度的和金钙配方。
背景技术
钙是人体内最重要的元素之一，参与一切生命活动过程，长期极度的低血钙使牙齿、骨骼发育不良，使佝偻病、软骨病发生，骨峰值偏低，将加速骨质疏松症的发生与发展。
自人们意识到缺钙以及低钙摄入的危险性以来，原有的含钙量较低的钙盐已不能适用于一般性缺钙的预防和治疗，还有一些钙制剂，由于其溶解度低，异味等原因，其应用受到限制。因此，生产并加工一种用于提高骨密度的和金钙配方较为重要。
发明内容
本发明的目的是为克服上述现有技术的不足，提供一种用于提高骨密度的和金钙配方，以解决上述问题。
为实现上述目的，本发明采用下述技术方案：一种用于提高骨密度的和金钙配方，各成分按重量比为：氨基酸螯合钙0.5～1g、胶原蛋白肽1～5g、杜仲雄花提取物0.1～1g、葛根提取物0.1～1g、低聚果糖1～3g、甜菊苷0.5～1g。
优选的，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、杜仲雄花提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
优选的，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、葛根提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
本发明的有益效果是：本发明根据男女性别不同、年龄不同，发生钙缺乏、钙流失、骨质疏松的机理不同，区分男用型和女用型配方，完美演绎高含量、快吸收、安全转运和长期储存的补钙原则，比传统补钙剂具有更好地补钙、固钙，提高骨密度的作用。
具体实施方式
为了更好地理解本发明，下面用具体实例来详细说明本发明的技术方案。
实施例一
一种用于提高骨密度的和金钙配方，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、杜仲雄花提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
成分的作用：
氨基酸螯合钙：由多种氨基酸与无机钙盐通过化学合成反应而生产的一种有机钙类物质。从而大大提高了动、植物对钙的吸收。
胶原蛋白肽：是一类以富含胶原蛋白的新鲜动物组织(包括皮、骨、筋、腱、鳞等)为原料，经过提取、水解、精制生产的，相对分子质量低于10000Da的产品。是一种营养物质，具有抗氧化性，可以使体内的自由基减少，可以抑制一些疾病，同时减缓衰老。
杜仲雄花提取物：具有养肝益肾的功效，可以抑制酒精对肝脏的损害，可用于养肝；可以有效的帮助睡眠，可用于改善高血压病人的失眠症状；可用于预防冠状动脉硬化、心绞痛、心肌缺血、心律失常、心跳加速；有通便排毒的功效，可以用于缓解便秘。
低聚果糖：促进生长发育和防止骨质疏松，同时还能够促进维生素B族元素以及叶酸的自然形成，提高人体的新陈代谢，提高免疫力和抗病毒能力。
甜菊苷：用于调整口感使用。
以上配方为男用型，完美演绎高含量、快吸收、安全转运和长期储存的补钙原则，比传统补钙剂具有更好地补钙、固钙，提高骨密度的作用。
实施例二
一种用于提高骨密度的和金钙配方，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、葛根提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
葛根提取物：降脂降糖。对于治疗高血糖，高血脂有显著疗效。同时，葛根黄酮是女性延缓衰老，美容，平衡的雌激素，更是延缓衰老的法宝。
以上配方为女用型，完美演绎高含量、快吸收、安全转运和长期储存的补钙原则，比传统补钙剂具有更好地补钙、固钙，提高骨密度的作用。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (3)
1.一种用于提高骨密度的和金钙配方，其特征在于，各成分按重量比为：氨基酸螯合钙0.5～1g、胶原蛋白肽1～5g、杜仲雄花提取物0.1～1g、葛根提取物0.1～1g、低聚果糖1～3g、甜菊苷0.5～1g。
2.根据权利要求1所述的一种用于提高骨密度的和金钙配方，其特征在于，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、杜仲雄花提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
3.根据权利要求1所述的一种用于提高骨密度的和金钙配方，其特征在于，各成分按重量比为：氨基酸螯合钙0.8g、胶原蛋白肽2g、葛根提取物0.5g、低聚果糖1.7g、甜菊苷0.8g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210336806.2A CN116889281A (zh) | 2022-04-01 | 2022-04-01 | 一种用于提高骨密度的和金钙配方 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210336806.2A CN116889281A (zh) | 2022-04-01 | 2022-04-01 | 一种用于提高骨密度的和金钙配方 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116889281A true CN116889281A (zh) | 2023-10-17 |
Family
ID=88312504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210336806.2A Pending CN116889281A (zh) | 2022-04-01 | 2022-04-01 | 一种用于提高骨密度的和金钙配方 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116889281A (zh) |
-
2022
- 2022-04-01 CN CN202210336806.2A patent/CN116889281A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7772428B2 (en) | Creatine hydroxycitric acids salts and methods for their production and use in individuals | |
| US6447809B1 (en) | Composition for promoting healthy bone structure | |
| US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
| US6541026B2 (en) | Nutritional composition, methods of producing said composition and methods of using said composition | |
| CN101132786B (zh) | 胍基乙酸的盐、加成化合物和络合化合物 | |
| US20060210650A1 (en) | Supplemental dietary composition for promoting weight loss | |
| CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
| CN1947600A (zh) | 防晒美容饮料 | |
| CN105211862A (zh) | 一种适用于女性润肤、美白养颜的营养包 | |
| MXPA04003188A (es) | Composicion para uso farmaceutico o dietetico para combatir perdida del cabello. | |
| CN114557448A (zh) | 一种易被人体吸收及改善人体软骨组织的制剂及制备方法 | |
| CN103535721B (zh) | 提高人体内谷胱甘肽浓度的组合物及其制备方法和应用 | |
| CN116889281A (zh) | 一种用于提高骨密度的和金钙配方 | |
| CN110584120A (zh) | 骨健康组合物 | |
| KR20190058346A (ko) | Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 | |
| AU2019101234B4 (en) | Formulation and method of use | |
| CN114747720A (zh) | 大豆肽复合粉组合物组合粉及其制备方法 | |
| CN107184598A (zh) | 一种宠物用心脏病复方片剂 | |
| CN103239461A (zh) | 复合维生素b注射液及其制备方法 | |
| CN113082059A (zh) | 一种防治骨质疏松症的组合物及其制备方法和应用 | |
| CN108719998A (zh) | 一种用于治疗骨关节炎的口服膳食补充药剂 | |
| CN114557928B (zh) | 一种美白祛黄护肤品及其制备方法 | |
| US20220062147A1 (en) | Skin Care Formulation for Treatment of Cellulite | |
| CN1181811C (zh) | 一种复方超细珍珠粉化妆品及制备方法 | |
| CN118141111A (zh) | 一种延年益寿的组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |